Skip to Content
Merck
All Photos(1)

Documents

Y0001257

Levetiracetam impurity D

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(2R)-2-(2-Oxopyrrolidin-1-yl)butanamide, (R)-Etiracetam

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H14N2O2
CAS Number:
Molecular Weight:
170.21
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1

InChI key

HPHUVLMMVZITSG-ZCFIWIBFSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation markEnvironment

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Iu V Popov et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(5 Pt 2), 48-52 (2013-06-07)
We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders
Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report.
Daniel M Almeida et al.
Pancreas, 42(1), 177-178 (2012-12-21)
Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens-Johnson syndrome in 2 cases.
Tu Anh Duong et al.
JAMA dermatology, 149(1), 113-115 (2013-01-18)
[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
S Yamashita et al.
No to hattatsu = Brain and development, 45(1), 64-66 (2013-04-19)
Gha-hyun Lee et al.
Seizure, 22(3), 185-188 (2013-01-03)
The efficacy and safety of the anti-convulsive drug levetiracetam (LEV) has been well documented but few clinical studies have investigated tolerance to LEV. The aim of this study was to evaluate the loss of the initial efficacy of LEV in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service